Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

Christopher C Butler; Jienchi Dorward; Ly-Mee Yu; Oghenekome Gbinigie; Gail Hayward; Benjamin R Saville; Oliver Van Hecke; Nick Berry; Michelle Detry; Christina Saunders; Mark Fitzgerald; Victoria Harris; Mahendra G Patel; Simon de Lusignan; Emma Ogburn; Philip H Evans; Nicholas PB Thomas; FD Richard Hobbs

The Lancet (2021) - Comments
doi: 10.1016/s0140-6736(21)00461-x issn: 0140-6736 pubmed: 33676597 issn: 1474-547x

Christopher C Butler, Jienchi Dorward, Ly-Mee Yu, Oghenekome Gbinigie, Gail Hayward, Benjamin R Saville, Oliver Van Hecke, Nick Berry, Michelle Detry, Christina Saunders, Mark Fitzgerald, Victoria Harris, Mahendra G Patel, Simon De Lusignan, Emma Ogburn, Philip H Evans, Nicholas PB Thomas, FD Richard Hobbs